Literature DB >> 28453332

Long-Term Intermittent Exposure to High Altitude Elevates Asymmetric Dimethylarginine in First Exposed Young Adults.

Nicole Lüneburg1, Patricia Siques2, Julio Brito2, Juan José De La Cruz3, Fabiola León-Velarde4, Juliane Hannemann1, Cristian Ibanez2, Rainer H Böger1.   

Abstract

Lüneburg, Nicole, Patricia Siques, Julio Brito, Juan José De La Cruz, Fabiola León-Velarde, Juliane Hannemann, Cristian Ibanez, and Rainer Böger. Long-term intermittent exposure to high altitude elevates asymmetric dimethylarginine in first exposed young adults. High Alt Med Biol. 18:226-233, 2017.-Hypoxia-induced dysregulation of pulmonary and cerebral circulation may be related to an impaired nitric oxide (NO) pathway. We investigated the effect of chronic intermittent hypobaric hypoxia (CIH) on metabolites of the NO pathway. We measured asymmetric and symmetric dimethylarginine (ADMA and SDMA) and monomethyl-L-arginine (L-NMMA) and assessed their associations with acclimatization in male draftees (n = 72) undergoing CIH shifts at altitude (3550 m) during 3 months. Sixteen Andean natives living at altitude (3675 m) (chronic hypobaric hypoxia [CH]) were included for comparison. In CIH, ADMA and L-NMMA plasma concentrations increased from 1.14 ± 0.04 to 1.95 ± 0.09 μmol/L (mean ± SE) and from 0.22 ± 0.07 to 0.39 ± 0.03 μmol/L, respectively, (p < 0.001 for both) after 3 months, whereas SDMA did not change. The concentrations of ADMA and L-NMMA were higher in CH (3.48 ± 0.07, 0.53 ± 0.08 μmol/L; p < 0.001) as compared with CIH. In both CIH and CH, ADMA correlated with hematocrit (r2 = 0.07, p < 0.05; r2 = 0.26; p < 0.01). In CIH, an association of ADMA levels with poor acclimatization status was observed. We conclude that the endogenous NO synthase inhibitors, ADMA and L-NMMA, are elevated in hypoxia. This may contribute to impaired NO production at altitude and may also be predictive of altitude-associated health impairment.

Entities:  

Keywords:  ADMA; acclimatization; acute mountain sickness; high altitude; intermittent hypoxia

Mesh:

Substances:

Year:  2017        PMID: 28453332      PMCID: PMC5649417          DOI: 10.1089/ham.2016.0123

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  42 in total

Review 1.  Invited review: Physiological consequences of intermittent hypoxia: systemic blood pressure.

Authors:  E C Fletcher
Journal:  J Appl Physiol (1985)       Date:  2001-04

2.  Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension.

Authors:  Jan T Kielstein; Stefanie M Bode-Böger; Gerrit Hesse; Jens Martens-Lobenhoffer; Attila Takacs; Danilo Fliser; Marius M Hoeper
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-04-28       Impact factor: 8.311

Review 3.  Arginine methylation an emerging regulator of protein function.

Authors:  Mark T Bedford; Stéphane Richard
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

4.  Asymmetric dimethylarginine is increased in asthma.

Authors:  Jeremy A Scott; Michelle L North; Mahroukh Rafii; Hailu Huang; Paul Pencharz; Padmaja Subbarao; Jaques Belik; Hartmut Grasemann
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

Review 5.  Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk.

Authors:  Rainer H Böger; Renke Maas; Friedrich Schulze; Edzard Schwedhelm
Journal:  Pharmacol Res       Date:  2009-07-22       Impact factor: 7.658

6.  Chronic hypoxia increases blood pressure and noradrenaline spillover in healthy humans.

Authors:  Jose A L Calbet
Journal:  J Physiol       Date:  2003-07-04       Impact factor: 5.182

7.  Time course of cardiovascular and hematological responses in rats exposed to chronic intermittent hypobaric hypoxia (4600 m).

Authors:  Patricia Siqués; Julio Brito; Fabiola León-Velarde; Luis Barrios; Juan José De La Cruz; Vasthi López; Rafael Herruzo
Journal:  High Alt Med Biol       Date:  2006       Impact factor: 1.981

8.  Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death.

Authors:  Gregory J Kato; Zeneng Wang; Roberto F Machado; William C Blackwelder; James G Taylor; Stanley L Hazen
Journal:  Br J Haematol       Date:  2008-03-17       Impact factor: 6.998

9.  Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension.

Authors:  S Mehta; D J Stewart; D Langleben; R D Levy
Journal:  Circulation       Date:  1995-09-15       Impact factor: 29.690

10.  Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort.

Authors:  Edzard Schwedhelm; Vanessa Xanthakis; Renke Maas; Lisa M Sullivan; Friedrich Schulze; Ulrich Riederer; Ralf A Benndorf; Rainer H Böger; Ramachandran S Vasan
Journal:  Clin Chem       Date:  2009-06-18       Impact factor: 8.327

View more
  10 in total

Review 1.  Impact of Zinc on Oxidative Signaling Pathways in the Development of Pulmonary Vasoconstriction Induced by Hypobaric Hypoxia.

Authors:  Karem Arriaza; Constanza Cuevas; Eduardo Pena; Patricia Siques; Julio Brito
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

2.  Effects of chronic intermittent hypobaric hypoxia on prostate-specific antigen (PSA) in Chilean miners.

Authors:  Diana Elizabeth Alcantara-Zapata; Shrikant I Bangdiwala; Daniel Jiménez; Manolis Kogevinas; Nella Marchetti; Carolina Nazzal
Journal:  Occup Environ Med       Date:  2021-05-11       Impact factor: 4.948

3.  Long-Term Intermittent Work at High Altitude: Right Heart Functional and Morphological Status and Associated Cardiometabolic Factors.

Authors:  Julio Brito; Patricia Siques; Rosario López; Raul Romero; Fabiola León-Velarde; Karen Flores; Nicole Lüneburg; Juliane Hannemann; Rainer H Böger
Journal:  Front Physiol       Date:  2018-03-22       Impact factor: 4.566

Review 4.  Reactive Oxygen Species and Pulmonary Vasculature During Hypobaric Hypoxia.

Authors:  Patricia Siques; Julio Brito; Eduardo Pena
Journal:  Front Physiol       Date:  2018-07-09       Impact factor: 4.566

5.  Asymmetric Dimethylarginine at Sea Level Is a Predictive Marker of Hypoxic Pulmonary Arterial Hypertension at High Altitude.

Authors:  Patricia Siques; Julio Brito; Edzard Schwedhelm; Eduardo Pena; Fabiola León-Velarde; Juan José De La Cruz; Rainer H Böger; Juliane Hannemann
Journal:  Front Physiol       Date:  2019-05-27       Impact factor: 4.566

6.  Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside.

Authors:  Juliane Hannemann; Julia Zummack; Jonas Hillig; Rainer Böger
Journal:  Pulm Circ       Date:  2020-04-14       Impact factor: 3.017

Review 7.  Dysregulation of the Nitric Oxide/Dimethylarginine Pathway in Hypoxic Pulmonary Vasoconstriction-Molecular Mechanisms and Clinical Significance.

Authors:  Juliane Hannemann; Rainer Böger
Journal:  Front Med (Lausanne)       Date:  2022-02-17

Review 8.  Activation of arginase II by asymmetric dimethylarginine and homocysteine in hypertensive rats induced by hypoxia: a new model of nitric oxide synthesis regulation in hypertensive processes?

Authors:  Vasthi López; Elena Uribe; Fernando A Moraga
Journal:  Hypertens Res       Date:  2020-11-04       Impact factor: 3.872

9.  Comparison of the Effectiveness of High-Intensity Interval Training in Hypoxia and Normoxia in Healthy Male Volunteers: A Pilot Study.

Authors:  Aleksandra Żebrowska; Dariusz Jastrzębski; Ewa Sadowska-Krępa; Marcin Sikora; Camillo Di Giulio
Journal:  Biomed Res Int       Date:  2019-09-22       Impact factor: 3.411

10.  L-arginine, asymmetric and symmetric dimethylarginine for early outcome prediction in unselected cardiac arrest victims: a prospective cohort study.

Authors:  Beata Csiszar; Zsolt Marton; Janos Riba; Peter Csecsei; Lajos Nagy; Kalman Toth; Robert Halmosi; Barbara Sandor; Peter Kenyeres; Tihamer Molnar
Journal:  Intern Emerg Med       Date:  2021-06-03       Impact factor: 3.397

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.